{"prompt": "['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'g) Antibiotic or antiviral medication within 4 weeks of baseline.', '15. Topical bland emollients (without pharmacological active ingredients) for pustular', 'psoriasis are allowed during the study, except within 24 hours prior to the study visits.', 'Rescue medication will be directed by the Investigator as needed. (Refer Section', '6.5.1).', '16. History of active TB or latent TB infection as indicated by a positive', 'QuantiFERON\u00ae. -TB Gold test at Screening or within 6 months prior to Day 1 (If the', 'test is indeterminate, it can be repeated only once), chest x-ray, and/or clinical', 'examination or has had active TB disease at any time in the past.', '17. History of drug, alcohol, or other substance abuse, or other factors (eg, excessive', 'caffeine use) limiting the ability to cooperate and to comply with the study protocol, as', 'determined by the Investigator.', '18. Pregnant or lactating females, or females who intend to become pregnant during the', 'study period.', '19. Donation of blood to a blood bank or in a clinical study (except at the Screening Visit)', 'within 4 weeks of study drug administration (within 2 weeks for plasma only).', '20. Blood transfusion within 4 weeks of study drug administration.', '21. Inability to tolerate IV drug administration.', '22. Any other physical, mental, or medical conditions, which, in the opinion of the', 'Investigator, make study participation inadvisable or could confound study', 'assessments.', '23. Clinically significant abnormality on chest x-ray at Screening or within 6 months prior', 'to Screening.', '24. Clinically significant abnormalities on 12-lead ECG at Screening.', '25. Evidence of clinically significant abnormality in urinalysis as determined by the', 'Investigator.', '26. Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV-1 or', 'HIV-2 antibodies.', '5.3', 'Lifestyle Considerations', 'Exposure to sunlight should be avoided during the study.', '5.4', 'Screen Failures', 'Screen failures are defined as subjects who consent to participate in the clinical study but are not', 'subsequently enrolled in the study. A minimal set of screen failure information is required to', 'ensure transparent reporting of screen failure subjects to meet the Consolidated Standards of', 'Reporting Trials publishing requirements and to respond to queries from regulatory authorities.', 'Minimal information includes demography, screen failure details, eligibility criteria, and any', 'SAE.', '29 October 2019', '30']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Individuals who do not meet the criteria for participation in this study (screen failure) may be', 'rescreened once after discussion with Medical Monitor. Rescreened subjects should not be', 'assigned the same subject number as for the initial screening.', '29 October 2019', '31']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', '6.0 STUDY TREATMENT', 'Study treatment is defined as any investigational treatment(s), marketed product(s), placebo, or', 'medical device(s) intended to be administered to a subject according to the study protocol.', '6.1', 'Study Treatment Administered', 'Eligible subjects will receive 750 mg of ANB019 IV in an open-label manner followed by', '3 doses of 100 mg SC administered on Days 29, 57, and 85.', 'Due to the potential for infusion reactions with protein drugs, ANB019 should be administered in', 'an environment under close supervision of a physician and where full resuscitation facilities are', 'immediately available. Allergic/anaphylactic reactions and infusion-related reactions typically', 'begin during, or within several hours of dose administration. The onset of symptoms may be', 'rapid, and some reactions may be life-threatening. The study treatment should be immediately', 'stopped and permanently withdrawn in case of severe allergic/anaphylactic reactions. For', 'treatment of allergic reactions, current local standard of care guidelines should be followed.', 'Study treatment details are provided in Table 1.', '29 October 2019', '32']\n\n###\n\n", "completion": "END"}